AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1611113
Drug: Epirubicin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (80 mg) intravesically 0, 24 and 48 h after TUR, followed by IFN‐alpha 2b as in Group 1.
Trial: 31959339
Drug: Cisplatin (C)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1-4 (CF)
Trial: 31959339
Drug: Cisplatin (C)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (C) 100 mg/m2 i.v., day 1; 5-fluorouracil (F) 1000 mg/m2 i.v., days 1-4 plus panitumumab (P) 9 mg/kg, i.v., day 1 (CFP)
Trial: 30967434
Drug: Dapagliflozin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (5 mg and 10 mg combined)
Trial: 19884426
Drug: Periarticular injections
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injections with corticosteroid (methylprednisolone acetate)
Trial: 19884426
Drug: Periarticular injections
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Periarticular injections without corticosteroid (no-steroid group)
Trial: 17537264
Drug: Acetaminophen (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (4 g/day for 3 consecutive days)
Trial: 11329985
Drug: Monthly group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly group visits with a primary care physician, nurse, and pharmacist
Trial: 7988347
Drug: Dilazep dihydrochloride
RxNorm normalized name: Levocetirizine Dihydrochloride
DrugBank: Dilazep (DB13715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilazep dihydrochloride (300 mg)
Trial: 3052894
Drug: Cefotetan (CTT)
RxNorm normalized name: Cefotetan
DrugBank: Cefotetan (DB01330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotetan (CTT) 2g single preoperative dose
Trial: 3052894
Drug: Cefoxitin (CFX)
DrugBank: Cefoxitin (DB01331)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefoxitin (CFX) 2g three perioperative doses plus 0.5g metronidazole
Trial: 28566227
Drug: Boosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted protease inhibitor plus lamivudine (once-daily lamivudine 300 mg)
Trial: 28566227
Drug: Boosted protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boosted protease inhibitor monotherapy (once-daily darunavir 800 mg or coformulation of lopinavir/ritonavir)
Trial: 24364193
Drug: Complex oral
RxNorm normalized name: vitamin B complex Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex oral splint procedure assisted by transcutaneous electrical nerve stimulation (TENS)
Trial: 24364193
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral splint
Trial: 20890666
Drug: Positive airway
RxNorm normalized name: VersaPAP Positive Airway Pressure Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positive airway pressure (PAP) therapy for 12 months
Trial: 20890666
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PAP therapy)
Trial: 11349245
Drug: Weekly sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly sessions plus routine inpatient treatment
Trial: 11349245
Drug: Routine inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine inpatient treatment only
Trial: 9152658
Drug: Intravenous procainamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous procainamide (10 mg.kg‐1)
Trial: 7700072
Drug: cilazapril, 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cilazapril, 2.5 mg/day (n = 12)
Trial: 30608395
Drug: Functional musculoskeletal
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional musculoskeletal therapy pathway
Trial: 27698176
Drug: Accelerated care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Accelerated care (deflation after 1 hour, 2 ml/10‐minute interval)
Trial: 23782489
Drug: V7 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: V7 (10 μg of heat-killed Mycobacterium vaccae)
Trial: 22379791
Drug: Acupuncture at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture at Back-shu points (Xinshu (BL 15), Pishu (BL 20), Gaohuang (BL 43)), once daily for 4 weeks
Trial: 20183647
Drug: ADHD on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADHD on stimulant medication
Trial: 11956266
Drug: Allogeneic melanoma
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic melanoma vaccine for 2 years
Trial: 495630
Drug: Carbenicillin plus
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbenicillin plus cefamandole by continuous infusion (C+CC)
Trial: 495630
Drug: Carbenicillin plus
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbenicillin plus cefamandole by intermittent infusion (C+IC)
Trial: 495630
Drug: Carbenicillin plus
RxNorm normalized name: carbenicillin
DrugBank: Carbenicillin (DB00578)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbenicillin plus tobramycin by continuous infusion (C+T)
Trial: 495630
Drug: Cure rates
RxNorm normalized name: Cocci-Cure C for Calves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cure rates regardless of antibiotic regimen
Trial: 28574453
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation at 800 mg/day
Trial: 19164186
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (10 mg once a day for children 10 to 24 months of age and 20 mg once a day for older children)
Trial: 16490909
Drug: Zoledronic acid,
RxNorm normalized name: Zoledronic Acid, Anhydrous
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid, 4 mg (n = 32)
Trial: 9255195
Drug: Once-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing of gentamicin (5.0 mg/kg)
Trial: 9255195
Drug: Twice-daily dosing
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily dosing of gentamicin (2.5 mg/kg)
Trial: 2950659
Drug: Polychemotherapy as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polychemotherapy as a component of combined and complex therapy
Trial: 24716680
Drug: Spironolactone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (15 to 45 mg daily)
Trial: 23963688
Drug: 75 mg/d
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/d of ASA (aspirin)
Trial: 23963688
Drug: 150 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/d of ASA (aspirin)
Trial: 18503621
Drug: Fentanyl-morphine combination
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl-morphine combination (fentanyl 13.33 mug/mL and morphine 1 mg/mL)
Trial: 18503621
Drug: Morphine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine alone (2 mg/mL)
Trial: 17070173
Drug: Higher cell
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher cell dose (10^8 cells)
Trial: 17070173
Drug: Lower cell
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower cell dose (10^7 cells)
Trial: 11193721
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition with glucose/amino acids/fat
Trial: 11193721
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition with glucose/amino acids
Trial: 8470423
Drug: Recombinant DNA
RxNorm normalized name: Recombinant DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant DNA hepatitis B vaccine, 40 micrograms given at months 0, 1, 2 and 6
Trial: 8470423
Drug: Booster injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Booster injection of 40 micrograms of hepatitis B vaccine in patients vaccinated before transplantation
Trial: 2878490
Drug: Multiple injections
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multiple injections (MI)
Trial: 26942318
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of propranolol (beta-adrenergic receptor antagonist) administered at encoding
Trial: 26942318
Drug: Propranolol administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol administered before memory retrieval
Trial: 16797593
Drug: Pramipexole as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole as add-on therapy to levodopa
Trial: 12653895
Drug: One intra-arterial
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One intra-arterial dose of cisplatin/lipiodol
Trial: 12653895
Drug: Four doses
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four doses of cisplatin/lipiodol (once every 3 months)
Trial: 10502211
Drug: Aspirin 100
RxNorm normalized name: aspirin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg daily (group A)
Trial: 10502211
Drug: Coumadin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coumadin plus aspirin (group CA)
Trial: 1936506
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 100 mg o.d. for 1 day (87 patients)
Trial: 1936506
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 100 mg b.i.d. for 1 day (83 patients)
Trial: 1936506
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 100 mg o.d. for 2 days (86 patients)
Trial: 7297067
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg vaginal suppository of 9-deoxo-16,16-dimethyl-9-methylene PGE2
Trial: 7297067
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg vaginal suppository of 9-deoxo-16,16-dimethyl-9-methylene PGE2
Trial: 7297067
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 15-methyl PGF2 alpha Tham added at 24 hours
Trial: 7297067
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 15-methyl PGF2 alpha Tham added at 36 hours
Trial: 7297067
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of PGE2
Trial: 7297067
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of 15-methyl PGF2 alpha methyl ester
Trial: 23263697
Drug: Post-chemotherapy interval
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-chemotherapy interval (PCI)
Trial: 21886189
Drug: Oral steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral steroid therapy (Prednisolone, 100 mg per day for 5 days)
Trial: 21886189
Drug: No oral
RxNorm normalized name: Beano Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No oral steroid (control group)
Trial: 3663426
Drug: Propranolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (80 mg or 120 mg)
Trial: 15040646
Drug: Macrolide therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macrolide therapy
Trial: 8659773
Drug: High thoracic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High thoracic epidural anesthesia (25 mL lidocaine)
Trial: 8659773
Drug: High thoracic
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High thoracic epidural anesthesia (25 mL lidocaine) combined with general anesthesia
Trial: 8659773
Drug: Low thoracic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low thoracic epidural anesthesia (12 mL lidocaine)
Trial: 31571128
Drug: Betahistine Dihydrochloride
RxNorm normalized name: Betahistine Dihydrochloride
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine Dihydrochloride 16 mg
Trial: 30096345
Drug: Small package
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small package size (350 g)
Trial: 30096345
Drug: Large package
RxNorm normalized name: Bos taurus large intestine preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large package size (1000 g)
Trial: 21751769
Drug: Guided imagery
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided imagery treatment group
Trial: 18515515
Drug: Foley catheter
RxNorm normalized name: Bard Foley Catheter 18FR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foley catheter plus low-dose oxytocin
Trial: 9660522
Drug: Barnidipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barnidipine (20 mg)
Trial: 4608708
Drug: Inactivated monovalent
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated monovalent A/Hong Kong vaccine
Trial: 4608708
Drug: Inactivated monovalent
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated monovalent A/England vaccine
Trial: 4608708
Drug: Influenza B
RxNorm normalized name: influenza B virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Influenza B vaccine
Trial: 26649424
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine (DexIV)
Trial: 16628507
Drug: Computer-based rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-based rehabilitation program (daily training for three weeks)
Trial: 12587100
Drug: Most promising
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Most promising experimental treatments selected at first interim analysis
Trial: 9441099
Drug: STH treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STH treatment (streptomycin, thiacetazone, isoniazid)
Trial: 3555382
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intravenous gammaglobulins
Trial: 2406323
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (standardized Alternaria extract)
Trial: 11473961
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration of GnRH agonist during the luteal phase (cL group)
Trial: 11473961
Drug: Long protocol
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long protocol (L group)
Trial: 3281057
Drug: RS‐86 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS‐86 (10 mg/d) plus glycopyrrolate (6 mg/d)
Trial: 29142966
Drug: Elemental Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental Mg 30 mmol/d
Trial: 29142966
Drug: Elemental Mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental Mg 15 mmol/d
Trial: 18242858
Drug: Exposure in
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure in vivo treatment (EXP)
Trial: 26651828
Drug: Graded activity
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Graded activity treatment (GA)
Trial: 20946333
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab 1.25 mg/0.05 ml
Trial: 18692170
Drug: methylphenidate/behavioural treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylphenidate/behavioural treatment (BT)
Trial: 9842405
Drug: Quinapril (angiotensin-converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (angiotensin-converting enzyme inhibitor)
Trial: 8923865
Drug: Insulin-like growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like growth factor I (IGF-I) 60 micrograms/kg
Trial: 30676012
Drug: Boswellia serrata
RxNorm normalized name: Boswellia Serrata
DrugBank: Indian frankincense (DB14275)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boswellia serrata lecithin-based delivery form (Casperome®) - one tablet/day
Trial: 30676012
Drug: Standard management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard management (SM) group: diet and, if needed, hyoscine butylbromide (Buscopan®) or papaverine hydrochloride + 10 mg of Atropa belladonna extract
Trial: 24494593
Drug: Computer-assisted self-management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer-assisted self-management plus problem-solving therapy
Trial: 20735289
Drug: Immunomodulatory therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunomodulatory therapy (IMT)
Trial: 19052246
Drug: Arm ergometer
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arm ergometer therapy (n = 10)
Trial: 19052246
Drug: Robotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robotic therapy (n = 10)
Trial: 19052246
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy (OT) group (control) (n = 10)
Trial: 15705982
Drug: Statin drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin drug therapy initiation protocol at hospital discharge
Trial: 15705982
Drug: Statin drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin drug therapy initiation protocol
Trial: 12907105
Drug: Lorazepam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (1 mg) administered intravenously 1 hour after surgery
Trial: 12907105
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intravenously 1 hour after surgery
Trial: 10603730
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg iodine/week
Trial: 10603730
Drug: Combined iodine/T4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined iodine/T4 treatment
Trial: 10603730
Drug: Single-T4 therapy
RxNorm normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-T4 therapy
Trial: 7002482
Drug: Tolmetin sodium
RxNorm normalized name: Tolmetin Sodium
DrugBank: Tolmetin (DB00500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolmetin sodium (1600 mg daily)
Trial: 7002482
Drug: Aloxiprin (initially
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloxiprin (initially 6 g daily, reduced to 4 g daily after 3 months)
Trial: 7002482
Drug: Phenylbutazone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone (400 mg daily)
Trial: 18613809
Drug: Disulfiram (≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (≤ 250 mg/day)
Trial: 1384304
Drug: Almokalant 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almokalant 4.5 mg intravenously over 10 minutes
Trial: 30232642
Drug: Pre-ovulatory follicular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-ovulatory follicular fluid (FF) levels of soluble urokinase plasminogen activator receptor (suPAR) in women with severe OHSS (n = 25)
Trial: 30232642
Drug: Pre-ovulatory follicular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-ovulatory follicular fluid (FF) levels of soluble urokinase plasminogen activator receptor (suPAR) in high-risk controls (n = 25)
Trial: 30232642
Drug: Pre-ovulatory follicular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-ovulatory follicular fluid (FF) levels of soluble urokinase plasminogen activator receptor (suPAR) in low-risk controls (n = 25)
Trial: 24607076
Drug: Toxic solution
RxNorm normalized name: Ellis Tonic
DrugBank: Zinc sulfate, unspecified form (DB14548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toxic solution (ionic hydroxylamine hydrochloride at 9mg/ml)
Trial: 19653815
Drug: Denosumab (30/120/180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (30/120/180 mg every 4 weeks or 60/180 mg every 12 weeks)